Novel TKI Highly Active in HER2-Mutant Lung Cancer

(MedPage Today) -- The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC) in a multicohort phase Ia/Ib study.
In the first cohort of...